These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7685236)

  • 21. Expression of sialyl Lewis(x) in hepatocellular carcinoma.
    Tori A; Harada A; Nakao A; Nonami T; Ito M; Takagi H
    Hepatogastroenterology; 1995; 42(6):939-43. PubMed ID: 8847049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
    Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma.
    Yamanaka N; Tanaka T; Tanaka W; Yamanaka J; Yasui C; Kuroda N; Takada M; Okamoto E
    Cancer; 1997 Apr; 79(8):1509-15. PubMed ID: 9118031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.
    Zheng H; Yang Y; Wang MC; Yuan SX; Tian T; Han J; Ni JS; Wang J; Xing H; Zhou WP
    Surg Oncol; 2016 Sep; 25(3):171-7. PubMed ID: 27566019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy.
    Wubetu GY; Morine Y; Teraoku H; Yoshikawa M; Ishikawa D; Yamada S; Ikemoto T; Saito YU; Imura S; Shimada M
    Anticancer Res; 2016 Feb; 36(2):757-62. PubMed ID: 26851035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.
    Cui M; Sun J; Hou J; Fang T; Wang X; Ge C; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J; Li H
    Tumour Biol; 2016 Oct; 37(10):13521-13531. PubMed ID: 27465557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
    Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
    Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis.
    Jin J; Niu X; Zou L; Li L; Li S; Han J; Zhang P; Song J; Xiao F
    Cancer Lett; 2016 Aug; 378(1):33-7. PubMed ID: 27160647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.
    Yin F; Han X; Yao SK; Wang XL; Yang HC
    World J Gastroenterol; 2016 Mar; 22(9):2837-43. PubMed ID: 26973422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma.
    Huang CS; Yu W; Cui H; Wang YJ; Zhang L; Han F; Huang T
    Int J Clin Exp Pathol; 2015; 8(6):7234-8. PubMed ID: 26261620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy.
    Tanimine N; Tanaka Y; Kobayashi T; Tashiro H; Miki D; Imamura M; Aikata H; Tanaka J; Chayama K; Ohdan H
    Cancer Immunol Res; 2014 Dec; 2(12):1142-7. PubMed ID: 25135909
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Imura S; Yamada S; Saito YU; Iwahashi S; Arakawa Y; Ikemoto T; Morine Y; Utsunomiya T; Shimada M
    Anticancer Res; 2017 Oct; 37(10):5877-5883. PubMed ID: 28982915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma.
    Nagao M; Nakajima Y; Kanehiro H; Hisanaga M; Aomatsu Y; Ko S; Tatekawa Y; Ikeda N; Kanokogi H; Urizono Y; Kobayashi T; Shibaji T; Kanamura T; Ogawa S; Nakano H
    Hepatology; 2000 Sep; 32(3):491-500. PubMed ID: 10960440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma.
    Umeda S; Kanda M; Sugimoto H; Tanaka H; Hayashi M; Yamada S; Fujii T; Takami H; Niwa Y; Iwata N; Tanaka C; Kobayashi D; Fujiwara M; Kodera Y
    BMC Cancer; 2017 Sep; 17(1):610. PubMed ID: 28863781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen.
    Suehiro T; Matsumata T; Itasaka H; Yamamoto K; Kawahara N; Sugimachi K
    Cancer; 1995 Aug; 76(3):399-405. PubMed ID: 8625120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical contribution to recurrence-free survival in patients with macrovascular-invasion-negative hepatocellular carcinoma.
    Tanaka S; Mogushi K; Yasen M; Noguchi N; Kudo A; Kurokawa T; Nakamura N; Inazawa J; Tanaka H; Arii S
    J Am Coll Surg; 2009 Mar; 208(3):368-74. PubMed ID: 19317998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and genetic polymorphism of necroptosis related protein RIPK1 is correlated with severe hepatic ischemia-reperfusion injury and prognosis after hepatectomy in hepatocellular carcinoma patients.
    Yao C; Li G; Cai M; Qian Y; Wang L; Xiao L; Thaiss F; Shi B
    Cancer Biomark; 2017 Jul; 20(1):23-29. PubMed ID: 28759952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
    Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.